Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes (vol 42, 10.1200/JCO.23.01994, 2024)

被引：2
|
作者：
Rastogi, Priya
O'Shaughnessy, Joyce
Martin, Miguel
Boyle, Frances
Cortes, Javier
Rugo, Hope S.
Goetz, Matthew P.
Hamilton, Erika P.
Huang, Chiun-Sheng
Senkus, Elzbieta
Tryakin, Alexey
Cicin, Irfan
Testa, Laura
Neven, Patrick
Huober, Jens
Shao, Zhimin
Wei, Ran
Andre, Valerie
Munoz, Maria
San Antonio, Belen
Shahir, Ashwin
Harbeck, Nadia
Johnston, Stephen
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17期
关键词：
D O I：
10.1200/JCO.24.00711
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2111 / 2111
页数：1
相关论文
共 50 条
  • [31] Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
    Murata, Takeshi
    Yoshida, Masayuki
    Shiino, Sho
    Watase, Chikashi
    Ogawa, Ayumi
    Shikata, Shohei
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    BREAST CANCER, 2023, 30 (06) : 1054 - 1064
  • [32] Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy
    Ito, Masahiro
    Amari, Masakazu
    Sato, Akiko
    Hikichi, Masahiro
    Tsurumi, Natsuko
    Otofuji, Hinano
    Saji, Shigehira
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 209 (03) : 503 - 512
  • [33] Real-world safety and efficacy of abemaciclib in combination with fulvestrant for advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer progressing after prior endocrine therapy: the Royal Marsden experience
    Kestenbaum, Samantha Rae
    Battisti, Nicolo Matteo Luca
    Nash, Tamsin
    Crimmin, Jane
    Okines, Alicia
    Parton, Marina
    McGrath, Sophie
    Turner, Nicholas
    Allen, Mark
    Johnston, Stephen
    Ring, Alistair
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 563 - 564
  • [34] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Takahashi, Masato
    Tokunaga, Eriko
    Mori, Joji
    Tanizawa, Yoshinori
    Van der Walt, Jan-Stefan
    Kawaguchi, Tsutomu
    Goetz, Matthew P.
    Toi, Masakazu
    BREAST CANCER, 2022, 29 (01) : 174 - 184
  • [35] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Masato Takahashi
    Eriko Tokunaga
    Joji Mori
    Yoshinori Tanizawa
    Jan-Stefan van der Walt
    Tsutomu Kawaguchi
    Matthew P. Goetz
    Masakazu Toi
    Breast Cancer, 2022, 29 : 174 - 184
  • [36] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [37] Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: An updated analysis
    Finn, Richard S.
    Rugo, Hope S.
    Gelmon, Karen
    Cristofanilli, Massimo
    Colleoni, Marco
    Loi, Sherene
    Schnell, Patrick
    Lu, Dongrui R.
    Theall, Kathy P.
    Mori, Ave
    Gauthier, Eric
    Bananis, Eustratios
    Turner, Nicholas C.
    Dieras, Veronique
    CANCER RESEARCH, 2020, 80 (04)
  • [38] EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC)
    Martin Jimenez, M.
    Bachelot, T.
    Barrios, C.
    Blackwell, K.
    Chia, S.
    De Laurentiis, M.
    Hurvitz, S.
    Janni, W.
    Kaufman, B.
    Loi, S.
    Schmid, P.
    Slamon, D.
    Hazell, K.
    Mondal, S.
    Shilkrut, M.
    Germa, C.
    Hortobagyi, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Analysis of subsequent therapy in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and-3
    Masuda, Norikazu
    Mukai, Hirofumi
    Inoue, Kenichi
    Rai, Yoshiaki
    Ohno, Shinji
    Ohtani, Shoichiro
    Shimizu, Chikako
    Hashigaki, Satoshi
    Muramatsu, Yasuaki
    Umeyama, Yoshiko
    Iwata, Hiroji
    Toi, Masakazu
    BREAST CANCER, 2021, 28 (02) : 335 - 345
  • [40] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
    Delevry, D.
    Le, Q. A.
    VALUE IN HEALTH, 2020, 23 : S32 - S33
12345